the United States for certain dental uses, but its regulatory status does not currently mean that it has FDA approval specifically as a treatment for severe childhood tooth decay. The American Academy of Pediatrics notes that SDF was cleared by the FDA as a Class II medical device in 2014 and has subsequently been used off-label to arrest cavities.
Therefore, the 2026 clinical trial represents an important step toward expanding its regulatory use rather than confirmation that a new pediatric indication has already been approved.🏥 Could Pediatricians Eventually Apply It?